Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Deferred Revenue (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Current Deferred Revenue for 14 consecutive years, with $111.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue changed N/A year-over-year to $111.9 million, compared with a TTM value of $111.9 million through Dec 2025, changed N/A, and an annual FY2025 reading of $2.4 million, changed N/A over the prior year.
  • Current Deferred Revenue was $111.9 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $2.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $150.9 million in Q2 2021 and bottomed at $866000.0 in Q3 2023.
  • Average Current Deferred Revenue over 4 years is $74.8 million, with a median of $84.3 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue soared 1511.09% in 2021, then crashed 99.33% in 2023.
  • Year by year, Current Deferred Revenue stood at $108.7 million in 2021, then crashed by 39.0% to $66.3 million in 2022, then crashed by 98.69% to $866000.0 in 2023, then skyrocketed by 12825.29% to $111.9 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ARWR at $111.9 million in Q4 2025, $2.4 million in Q3 2025, and $23.0 million in Q2 2025.